Question · Q4 2025
Bennett, on behalf of Salim Syed, inquired about the key drivers behind Attruby's consistent growth and competitive differentiation, especially as competitors' growth appears to be slowing, and what feedback is resonating with physicians and patients.
Answer
Matt Outten, Chief Commercial Officer, highlighted the strength of BridgeBio's field team, Attruby's superior data (near-complete stabilization, rapid time to separation), and disciplined focus on patient and HCP needs. Neil Kumar, CEO, added that the launch is experiencing a second wave of acceleration driven by rapid patient identification and new prescribers.
Ask follow-up questions
Fintool can predict 
BBIO's earnings beat/miss a week before the call